Dr. Alexander Rivkin, globally recognized pioneer in non-surgical rhinoplasty and facial aesthetic procedures, has co-authored a pivotal Phase 2B clinical study demonstrating the safety and efficacy of onabotulinumtoxinA (Botox Cosmetic) for treating masseter muscle prominence. The comprehensive research, titled "A Controlled Phase 2b Trial to Assess the Efficacy and Safety of a Single Intervention of OnabotulinumtoxinA for Treating Masseter Muscle Prominence," has been published in the prestigious Aesthetic Surgery Journal. 

Dr. Rivkin collaborated with leading international researchers including Dr. Steven Liew, Dr. Derek Jones, Dr. Steven Dayan, Dr. Sabrina Fabi, and Dr. Brian Biesman on this landmark multicenter, randomized, double-blind, placebo-controlled trial. The study evaluated the effectiveness of onabotulinumtoxinA in reducing masseter muscle prominence—a condition that can create a wide, square jawline appearance and affect facial aesthetics.

The research findings demonstrated that onabotulinumtoxinA administered in single or multiple treatments over one year was associated with significant reductions in masseter muscle volume and prominence severity, while maintaining an acceptable safety profile. The study represents a major advancement in understanding how botulinum toxin can be safely and effectively used for lower facial contouring.

Read more at PR Newswire >>